For Diagnostic Labs: How to Escape the Test Price War
Every year the tests you run get cheaper to copy and harder to differentiate. The way out isn't a cheaper test — it's owning the layer above it: the interpretation.
Ask a lab owner what happened to margins on routine panels over the last decade and you'll hear the same story: the tests didn't get worse, they got common. When every competitor runs the same assay on the same class of analyser, procurement compares the only variable left — price. The way out is not a cheaper test. It's selling something a price list can't capture.
Why good labs lose on price
Here is the uncomfortable mechanism. In most of the markets we operate in, nothing on a quotation distinguishes a rigorous report from a thin one. In India there is no CLIA equivalent and NABL accreditation is voluntary — so when two quotes land on a procurement desk, quality is invisible and price is the only signal that survives the comparison. Losing that comparison doesn't mean your lab is worse. It means the thing you're better at was never visible in the first place.
If the difference between you and the cheap option only shows up after purchase, procurement is right to ignore it.
The layer above the test
A test result is a number. What clinicians and end-clients actually pay for is the answer: what these numbers mean together, for this person, with what confidence. That interpretation layer is where differentiation lives, because it cannot be copied by buying the same analyser. One partner delivers separate DNA, gut microbiome and blood reports under your brand. The laboratory's doctors keep the final say. Every interpretation is traced to curated evidence, and clinical findings are routed to a qualified human. Decision-support for the treating professional, not a verdict from a black box.
What it looks like operationally
Your wet-lab keeps doing what it does. The interpretation platform sits on top: your test output goes in, and separate DNA, microbiome and blood reports come back under your name. Pricing is set on the pilot call. Most labs start light — an interpretation overlay on panels they already run — then add DNA and microbiome as their own reports as clients ask for them. Because the lab already exists, going live is an integration project, not a build. (For the full build-vs-buy comparison, see in-house vs white-label, or explore the Evolveme platform.)
Making quality legible before the price conversation
The deeper win is commercial. A lab selling interpreted, evidence-traced reports has something to show a prospect that a price list can't flatten: run the interpretation on their own past cases, show what the cheaper report would have missed, and put the citations where a non-specialist can check them. That is how quality becomes visible before the pricing conversation — and how the conversation stops being about price. We operate this model with 39 partners across 11 countries, under ISO 9001:2015 (pursuing ISO 13485), GDPR-compliant.
If you run a diagnostic lab and want the interpretation layer under your brand, start at diagnostic laboratories, open the laboratory proof packet, then book a pilot call against your actual volumes.